| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| ARS | An annual report to security holders |
Annual Filings
|
||
| DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") |
Proxy Filings
|
||
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| CT ORDER | CT ORDER |
Other
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
